EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN UKRAINE
DOI:
https://doi.org/10.21856/j-PEP.2024.1.02Keywords:
Chronic kidney disease, diabetes mellitus, risk of end-stage renal disease, albuminuriaAbstract
The article reports on the prevalence of chronic kidney disease (CKD) in Ukrainian diabetic patients. A total of 194 patients who seeking an appointment with an endocrinologist underwent CKD screening.
Materials and methods. The mean age of the patients was 64.82±0.88 years, and the duration of diabetes mellitus amounted to 9.29±0.60 years. Of these, 53.1% were female and 46.9% were male. Out of the screened patients, 79.4% had type 2 diabetes mellitus, 3.6% had type 1 diabetes mellitus, 9.3% had prediabetes, and 7.7% had other types of diabetes. We diagnosed CKD by calculating the estimated glomerular filtration rate (GFR) based on the creatinine level using the CKD-EPI Creatinine formula and determining albuminuria as the albumin-to-creatinine ratio.
Results. Among diabetic patients, 26.8% had stage 1 CKD, 42.3% had stage 2, 21.6% had stage 3a, 8.2% had stage 3с, and 0.5% had each of stage 4 and 5. 70.6% of patients were found to have albumin-to-creatinine ratio (ACR) A1, 21.6% – A2, and 7.7% – A3. Of these, 30.0% were at high and very high risk of developing end-stage CKD. The regression analysis revealed a negative correlation between the duration of diabetes mellitus and the level of GFR, B (95% CI) = -0.102 (-0.179/-0.26), p = 0.009, and a positive correlation with ACR, B (95% CI) = 2.87 (0.089/5.605), p = 0.043.
Conclusions. Among the examined patients with diabetes mellitus, 73.2% had stage 2-5 chronic kidney disease, and 29.3% had stage A2 and A3 albuminuria. Of these, 30% belong to the high- and very high-risk group for developing end-stage chronic kidney disease, requiring regular monitoring of glomerular filtration rate and albuminuria at least 3-4 times a year and conservative treatment. The duration of diabetes is a negative risk factor for chronic kidney disease. Hence, chronic kidney disease screening should be performed in all patients with diabetes with no exception.
References
Jager KJ, Kovesdy C, Langham R, et al. Kidney Int 2019;96: 1048-1050. https://doi.org/10.1016/j.kint.2019.07.012.
KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease, available at: https://kdigo.org/guidelines/diabetes-ckd/
Zhyty dobre z hvoroboju nyrok: Vsesvitnij den' nyrky 2021. https://doi.org/10.22141/2307-1257.10.2.2021.234330
Mills KT, Xu Y, Zhang W, et al. Kidney Int 2015;88: 950-957. https://doi.org/10.1038/ki.2015.230.
IDF Diabetes Atlas 2023, available at: https://diabetesatlas.org/atlas-reports/
IDF Diabetes Atlas 2023. Diabetes and kidney disease, available at: https://diabetesatlas.org/atlas/diabetes-and-kidney-disease/
Hill NR, Fatoba ST, Oke JL, et al. PLoS One 2016; 11. https://doi.org/10.1371/journal.pone.0158765.
Centers for Disease Control and Prevention Chronic kidney disease (CKD) surveillance system: 2021, available at: https://nccd.cdc.gov/ckd/default.aspx
Gatwood J, Chisholm-Burns M, Davis R, et al. PLoS One 2018;13. https://doi.org/10.1371/journal.pone.0192712.
Bairey Merz CN, Dember LM, Ingelfinger JR, et al. Nat Rev Nephrol 2019;15:776-783. https://doi.org/10.1038/s41581-019-0208-6.
Silbiger SR, Neugarten J. Am J Kidney Dis 1995;25: 515-533. https://doi.org/10.1016/0272-6386(95)90119-1.
Hecking M, Bieber BA, Ethier J, et al. PLoS Med 2014;11. https://doi.org/10.1371/journal.pmed.1001750.
Iseki K, Nakai S, Shinzato T, et al. Ther Apher Dial 2005;9: 407-411. https://doi.org/10.1111/j.1744-9987.2005.00318.x.
Neugarten J, Golestaneh L. Mayo Clin Proc 2019;94: 1339-1356. https://doi.org/10.1016/j.mayocp.2018.12.024.
Kovesdy CP. Kidney Int Suppl (2011). 2022;12(1): 7-11. https://doi.org/10.1016/j.kisu.2021.11.003.
Ko K, Kwon MJ, Ryu S, et al. J Clin Lab Anal 2016;30(5): 424-430. https://doi.org/10.1002/jcla.21874.
ISSN 
ISSN 
